Published in Cancer Weekly, August 2nd, 2005
According to a study from England, "vascular endothelial growth factor (VEGF) is a proangiogenic cytokine that is expressed highly in many solid tumors often correlating with a poor prognosis. In this study, we investigated the expression of VEGF and its receptors in bone metastases from primary human breast tumors and further characterized its effects on osteoclasts in vitro."
"Breast cancer metastases to bone were immunohistochemically stained for VEGF and its receptors...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.